Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Saved in:
| Title: | Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. |
|---|---|
| Authors: | Patel KR; Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA., Nguyen PL; Brigham and Women's Hospital, Boston, MA, USA., Proudfoot JA; Veracyte, Inc, South San Francisco, CA, USA., Liu Y; Veracyte, Inc, South San Francisco, CA, USA., Pra AD; University of Miami Cancer Center, Miami, FL, USA., Spratt DE; UH Cleveland Medical Center, Cleveland, OH, USA., Pollack A; University of Miami Cancer Center, Miami, FL, USA., Sandler HM; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Efstathiou JA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lawton C; Medical College of Wisconsin, Milwaukee, WI, USA., Simko JP; UCSF Medical Center-Mission Bay, San Francisco, CA, USA., Rosenthal SA; Sutter Cancer Centers Radiation Oncology Services, Roseville, CA, USA., Zeitzer KL; Einstein Medical Center, Accruals for Thomas Jefferson University Hospital, Philadelphia, PA, USA., Mendez LC; London Regional Cancer Program, London, ON, Canada., Hartford AC; Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, NH, USA., Hall WA; Froedtert and the Medical College of Wisconsin, Milwaukee, WI, USA., Desai AB; Summa Health System, Akron, OH, USA., Pugh SL; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; ACR, American College of Radiology, Philadelphia, PA, USA., Davicioni E; Veracyte, Inc, South San Francisco, CA, USA., Tran PT; Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA. Electronic address: phuoc.tran@som.umaryland.edu., Feng FY; UCSF Medical Center-Mission Bay, San Francisco, CA, USA. Electronic address: felix.feng@ucsf.edu. |
| Source: | European urology oncology [Eur Urol Oncol] 2026 Apr; Vol. 9 (2), pp. 413-421. Date of Electronic Publication: 2024 Nov 13. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
